Advanced therapies like CAR-T and bispecifics are reshaping oncology, but their success now depends as much on delivery as on science. This white paper explores how FDA and CMS policy changes, mounting real-world evidence, and payer pressure are accelerating a shift toward outpatient and community delivery.
Inside, you’ll find:
-
Key data showing >75% of CAR-T delivered outpatient with safety equivalent to inpatient care.
-
The regulatory, clinical, and payer drivers behind this transition.
-
Practical frameworks for biopharma and providers to scale safely and align with payer expectations.
Complete the form below to download the white paper to learn how delivery models are shaping the future of advanced therapies and how to prepare your organization for what’s next.
